Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation

被引：0
|
作者：
Dong, X. [1 ]
Jia, W. [2 ]
Gu, D. [2 ]
Guo, R. [3 ]
Miao, L. [4 ]
Wang, W. [5 ]
Xu, C. [6 ]
Chen, R. [2 ]
Xia, X. [2 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, Wuhan, Hubei, Peoples R China
[2] Geneplus Beijing, Beijing, Peoples R China
[3] Jiangsu Prov Hosp, Oncol, Nanjing, Jiangsu, Peoples R China
[4] Nan Jing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China
[5] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
T790M; EGFR-TKIs therapy; next generation sequencing (NGS);
D O I：
10.1016/j.jtho.2018.08.583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-27
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [1] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
    Oya, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S622 - S622
  • [2] Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation
    Oya, Y.
    Yoshida, T.
    Tanaka, K.
    Kuroda, H.
    Shimizu, J.
    Horio, Y.
    Sakao, Y.
    Inaba, Y.
    Hida, T.
    Yatabe, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs.
    Oya, Yuko
    Yoshida, Tatsuya
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Bronchoalveolar Lavage as an Alternative to Rebiopsy for Detection of T790M Mutation in NSCLC Patients with Acquired Resistance to EGFR-TKIs
    Kim, H.
    Hur, J. Y.
    Kim, I. A.
    Lee, S.
    Kim, W. S.
    Lee, K. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S368 - S368
  • [5] Clinical Characteristics of T790M in Pre and Post Treatment with EGFR TKIs
    Ke, Ee
    Zhang, Qiuyi
    Zhou, Qing
    Wu, Yilong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S778 - S778
  • [6] Clinical characteristics of T790M in pre and post treatment with EGFR TKIs
    Ke, E.
    Zhang, Q.
    Zhou, Q.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [7] Origin of the T790M mutation and its impact on the clinical outcomes of I patients with lung adenocarcinoma receiving EGFR-TKIs
    Dong, Yujie
    Zhou, Zhen
    Wang, Jianguo
    Ma, Li
    Liu, Zichen
    Wang, Yuxuan
    Song, Jing
    Zhang, Shucai
    Che, Nanying
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (05) : 946 - 951
  • [8] Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR
    Wu, Shang-Gin
    Gow, Chien-Hung
    Chen, Yi-Ling
    Liu, Yi-Nan
    Tsai, Meng-Feng
    Shih, Jin-Yuan
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (02) : 352 - 363
  • [9] EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
    Liang, Zhiyong
    Cheng, Ying
    Chen, Yuan
    Hu, Yanping
    Liu, Wei-Ping
    Lu, You
    Wang, Jie
    Wang, Ye
    Wu, Gang
    Ying, Jian-Ming
    Zhang, He-Long
    Zhang, Xu-Chao
    Wu, Yi-Long
    CANCER LETTERS, 2017, 403 : 186 - 194
  • [10] Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition
    Zhou, Juan
    Hu, Qiaoting
    Zhang, Xi
    Zheng, Jihua
    Xie, Bo
    Xu, Zhiyong
    Zhang, Weimin
    ONCOLOGY REPORTS, 2018, 39 (04) : 1783 - 1792
12345